Baylor Genetics is a diagnostic genomics company and a joint venture between Baylor College of Medicine and HU Group Holdings, Inc. With nearly 50 years of operational history and over 4 million tests performed worldwide, it provides a comprehensive range of genetic testing services spanning rare diseases, pediatric genetics, reproductive health, hereditary cancer, and metabolic disorders.
The company's testing platform covers the full spectrum of modern genomic diagnostics, including:
- Whole Genome Sequencing (WGS)
- Whole Exome Sequencing (WES)
- RNA Sequencing
- Chromosomal Microarray Analysis (CMA)
- Specialized diagnostic assays and multiomics approaches
Clinical results are interpreted by a team of PhDs, MDs, laboratory directors, and genetic counselors. Baylor Genetics holds CLIA, CAP, and New York State Department of Health accreditations, and operates globally. The organization traces its involvement in genetic testing innovation to the early development of chromosomal microarray analysis and whole exome sequencing.
As a joint venture with Baylor College of Medicine, the company maintains close ties to academic medicine and clinical research, with a focus on translating genomic data into actionable diagnostic insights for patients and healthcare providers.
